These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37440354)

  • 41. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
    Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
    Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
    Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
    Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
    Gerds AT; Yu J; Scherber RM; Paranagama D; Kish JK; Visaria J; Singhal M; Verstovsek S; Pemmaraju N
    Acta Haematol; 2022; 145(4):448-453. PubMed ID: 35008087
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ruxolitinib (Jakafi) for myelofibrosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1387):27-8. PubMed ID: 22469651
    [No Abstract]   [Full Text] [Related]  

  • 45. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
    Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
    Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
    Ikeda Y; Yamanouchi J; Takenaka K
    Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
    [No Abstract]   [Full Text] [Related]  

  • 47. Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story.
    Barosi G; Gale RP
    Blood Adv; 2022 Apr; 6(7):2331-2333. PubMed ID: 35240682
    [No Abstract]   [Full Text] [Related]  

  • 48. Long-term outcome of treatment with ruxolitinib in myelofibrosis.
    Tefferi A; Litzow MR; Pardanani A
    N Engl J Med; 2011 Oct; 365(15):1455-7. PubMed ID: 21995409
    [No Abstract]   [Full Text] [Related]  

  • 49. Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience.
    Gangat N; McCullough K; Al-Kali A; Begna KH; Patnaik MM; Litzow MR; Hogan W; Shah M; Alkhateeb H; Mangaonkar A; Foran JM; Palmer JM; Pardanani A; Tefferi A
    Br J Haematol; 2022 Aug; 198(4):e54-e58. PubMed ID: 35614565
    [No Abstract]   [Full Text] [Related]  

  • 50. Ruxolitinib for myelofibrosis therapy: current context, pros and cons.
    Pardanani A
    Leukemia; 2012 Jul; 26(7):1449-51. PubMed ID: 22285996
    [No Abstract]   [Full Text] [Related]  

  • 51. Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.
    Breccia M; Baratè C; Benevolo G; Bonifacio M; Elli EM; Guglielmelli P; Maffioli M; Malato A; Mendicino F; Palumbo GA; Pugliese N; Rossi E; Rumi E; Sant'Antonio E; Ricco A; Tiribelli M; Palandri F
    Ann Hematol; 2020 Jan; 99(1):65-72. PubMed ID: 31832751
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emerging drugs for myelofibrosis.
    Atallah E; Verstovsek S
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis.
    Di Raimondo C; Rao L; Lozzi F; Lombardo P; Silvaggio D; Vellucci L; Tofani L; Campione E; Bianchi L
    Dermatol Ther; 2022 May; 35(5):e15421. PubMed ID: 35249252
    [No Abstract]   [Full Text] [Related]  

  • 54. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.
    Guglielmelli P; Ghirardi A; Carobbio A; Masciulli A; Maccari C; Mora B; Rumi E; Triguero A; Finazzi MC; Pettersson H; Paoli C; Mannelli F; Vanni D; Rambaldi A; Passamonti F; Alvarez-Larràn A; Andreasson B; Vannucchi AM; Barbui T
    Blood Adv; 2022 Jan; 6(2):373-375. PubMed ID: 34753179
    [No Abstract]   [Full Text] [Related]  

  • 55. Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib.
    Zhou A; Kong T; Fowles JS; Jung CL; Allen MJ; Fisher DAC; Fulbright M; Nemeth E; Ganz T; Oh ST
    Br J Haematol; 2022 May; 197(4):e49-e52. PubMed ID: 35128632
    [No Abstract]   [Full Text] [Related]  

  • 56. Ruxolitinib: in the treatment of myelofibrosis.
    Yang LP; Keating GM
    Drugs; 2012 Nov; 72(16):2117-27. PubMed ID: 23061804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
    Palandri F; Palumbo GA; Elli EM; Polverelli N; Benevolo G; Martino B; Abruzzese E; Tiribelli M; Tieghi A; Latagliata R; Cavazzini F; Bergamaschi M; Binotto G; Crugnola M; Isidori A; Caocci G; Heidel F; Pugliese N; Bosi C; Bartoletti D; Auteri G; Cattaneo D; Scaffidi L; Trawinska MM; Stella R; Ciantia F; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Iurlo A; Vianelli N; Cavo M; Breccia M; Bonifacio M
    Blood Cancer J; 2021 Jan; 11(1):4. PubMed ID: 33414394
    [No Abstract]   [Full Text] [Related]  

  • 59. Ruxolitinib for myelofibrosis.
    Haznedaroglu IC
    N Engl J Med; 2012 May; 366(21):2032; author reply 2032-5. PubMed ID: 22621635
    [No Abstract]   [Full Text] [Related]  

  • 60. Ruxolitinib for myelofibrosis.
    Koschmieder S; Koppelle A; Seifert H
    N Engl J Med; 2012 May; 366(21):2031-2; author reply 2032-4. PubMed ID: 22621634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.